In line with this, in the Rotterdam study, patients with T2D carrying the CYP2C9*3 allele required a lower dose of tolbutamide to regulate glycaemia, compared to patients with the wild‐type CYP2C9 genotype.9 Here, CYP2C9 is linked to type 2 diabetes mellitus.